Sparrow Pharmaceuticals is developing targeted therapies for conditions of corticosteroid excess - associated with either the natural corticosteroid cortisol due to a tumor or long-term use of a corticosteroid drug such as prednisone. Sparrow's pipeline is led by SPI-62 in Phase 2 clinical development.
Location: United States, Oregon, Portland
Member count: 1-10
Total raised: $50M
Founded date: 2013
Investors 4
Date | Name | Website |
20.05.2021 | US Venture... | usvp.com |
- | Puget Soun... | pugetsound... |
- | OrbiMed | orbimed.co... |
- | Slojo Inve... | slojoinves... |
Funding Rounds 1
Date | Series | Amount | Investors | Deal News |
18.05.2021 | Series A | $50M | - | orbimed.co... |
Mentions in press and media 7
Date | Title | Description | Category | Author | Source |
18.05.2021 | Sparrow Ph... | - | - | - | usvp.com/n... |
18.05.2021 | Sparrow Ph... | - | - | - | orbimed.co... |
18.05.2021 | Sparrow Ph... | Sparrow Pharmaceuticals, an em... | - | - | marketscre... |
13.04.2016 | It’s offic... | A quartet of companies on Wedn... | - | - | medcitynew... |
13.04.2016 | Day 2: INV... | healthbox: the speed at which ... | - | - | medcitynew... |
- | Day 2: INV... | Participate in the MedCity INV... | - | - | medcitynew... |
- | It’s offic... | Today’s a day where you could ... | - | - | medcitynew... |